Minretumomab
Based on 1 publication(s) in Google Scholar
Minretumomab (CC-49) is a murine monoclonal antibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab is used in cancer and immunity research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 97.37%
- CAS 番号: 195189-17-4
- 分子量:146.06 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
MedChemExpress(MCE)の使用を引用している文献 Minretumomab
More
生物活性
製品説明
Isotype
Mouse IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
臨床実験
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG1-kappa
アプリケーション
ELISA, FACS, Functional assay
Verified Bioactivity
-
Flow cytometric analysis of 1.5×106 NCI-H1703 cells with Minretumomab (HY-P99732, red). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Goat Anti-Mouse IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Mouse IgG1 kappa Isotype Control (HY-P99977, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
化学情報
-
CAS 番号 195189-17-4
-
性状 Liquid
-
分子量 146.06 kDa
-
Color Colorless to light yellow
-
SMILES
[Minretumomab]
-
別名
CC-49
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
純度とドキュメンテーション
-
データシート (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Graves SS, et al. Combination therapy with Pretarget CC49 radioimmunotherapy and gemcitabine prolongs tumor doubling time in a murine xenograft model of colon cancer more effectively than either monotherapy. Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3712-21. [Content Brief]
[2]. Sheikh N. Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute. Curr Opin Mol Ther. 2003 Aug;5(4):428-32. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)